England Rolls Out World-First Gonorrhoea Vaccine
Hoping to curb soaring infection rates and ease NHS burden.
England has pioneered a new public health initiative, launching the United Kingdom’s first gonorrhoea vaccination program. This pioneering effort aims to prevent a significant number of new infections and substantially reduce the strain on National Health Service resources.
Targeting High-Risk Groups
The program will offer GSK’s 4CMenB vaccine free of charge to individuals identified as being at the highest risk of contracting this sexually transmitted infection. This includes gay and bisexual men who have had multiple sexual partners or have been diagnosed with a bacterial STI within the last twelve months.
The Department of Health and Social Care anticipates that vaccinating those most vulnerable will help curb the alarming rise in gonorrhoea cases. Projections suggest the program could avert as many as 100,000 infections over time, potentially saving the NHS more than £7.9 million in funding over the next decade.
Rising Infections Prompt Action
This preventative measure comes as gonorrhoea diagnoses in England have reached unprecedented levels. In 2023, a record 85,000 cases were reported, a threefold increase compared to 2012. A key driver of this surge is the growing prevalence of antibiotic-resistant strains, a challenge the new vaccine is designed to confront.
Repurposed Vaccine Faces New Challenge
The 4CMenB vaccine, originally developed by GSK to protect against meningococcal B disease, received European approval in 2013 and was introduced into the UK’s routine childhood immunisation schedule in 2015. Its use for gonorrhoea prevention, however, is currently considered off-label.
Following encouraging evidence suggesting its potential efficacy against gonorrhoea, the UK’s Joint Committee on Vaccination and Immunisation reviewed the vaccine’s suitability in late 2023. After evaluating immunogenicity data and cost-effectiveness analyses, the committee recommended the targeted vaccination strategy for high-risk populations.
Expert Endorsement and Future Treatments
Dr. **Sema Mandal**, a consultant epidemiologist at the UK Health Security Agency, welcomed the rollout. “This rollout is hugely welcome as we’re currently seeing very concerning numbers of gonorrhoea, including even more worryingly antibiotic-resistant gonorrhoea,”
she stated. “The vaccine will give much-needed protection to those that need it most – making the UK a world leader in the fight against gonorrhoea.”
GSK is also advancing a new oral antibiotic, gepotidacin, for treating gonorrhoea in adolescents and adults. Recent Phase III trial results for this candidate, marketed as Blujepa, have shown strong efficacy against antibiotic-resistant strains. The US Food and Drug Administration approved Blujepa in March 2025 for treating urinary tract infections.
